Royalty Pharma (RPRX) Q4 2025 earnings summary

Executive summary

• Achieved double-digit growth in 2025, with Portfolio Receipts up 16% to $3.254 billion and Royalty Receipts up 13%, surpassing guidance and driven by strong capital deployment and portfolio performance.

• Internalized external manager, resulting in significant cost savings, improved alignment, and governance.

• Deployed $2.6 billion in royalty transactions, including a record year for synthetic royalty deals and major transactions across multiple therapies.

• Returned $1.7 billion to shareholders through $1.2 billion in share repurchases and over $500 million in dividends, with a 7% dividend increase in Q1 2026.

• Positive clinical and regulatory updates for key therapies, including FDA approvals and Phase 3 results for Myqorzo, Tremfya, TEV-'749, deucrictibant, and Trodelvy.

Financial highlights

• FY 2025 Royalty Receipts were $3.127 billion (+13% YoY), Portfolio Receipts $3.254 billion (+16% YoY), with Q4 Royalty Receipts at $856 million (+17% YoY).

• Adjusted EBITDA for FY 2025 was $2.966 billion (91.1% of Portfolio Receipts); Portfolio Cash Flow $2.724 billion (83.7% of Portfolio Receipts).

• Return on Invested Capital was 15.8% and Return on Invested Equity was 22.8% for 2025.

• Net interest paid was $242 million for 2025; margin remained high at 84%.

• Ended 2025 with $619 million in cash and $9.2 billion in total debt.

Outlook and guidance

• 2026 guidance: Portfolio Receipts of $3.275–$3.425 billion, Royalty Receipts growth of 3%–8%.

• Operating and professional costs projected at 5.5%–6.5% of Portfolio Receipts in 2026, with $350–$360 million in interest paid.

• Guidance reflects expected loss of exclusivity for Promacta, biosimilar Tysabri launch, and IRA impact.

• Milestones and other contractual receipts expected to decrease from $128 million in 2025 to $60 million in 2026.

• Equity performance awards expected to be $85 million in 2026.